Agendia expands its business activities in Germany

26-Oct-2016 - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the expansion of its business activities in Germany. The Company has launched the “BRIDGE” patient initiative to enable more physicians and their patients to access the additional benefits of ...

Agendia Co-Founder Wins European Inventor Award for Breast Cancer Test

19-Jun-2015 - Agendia co-founder and Chief Research Officer, Laura van't Veer, Ph.D., has won the European Inventor Award in the SME category. The European Inventor Award is a innovation award presented by the European Patent Office, with only 15 inventors nominated in a total of five categories worldwide.The ...

Agendia Receives €1.27 Million in Funding from the EU’s Seventh Framework Programme

Company will develop companion diagnostics with consortiums of leading European cancer centers and translational research groups

22-Jul-2011 - Agendia announced that, together with collaborators in clinical centers and translational research groups, it has launched the RATHER (Rational Therapy for Breast Cancer) and COLTHERES (Colon Cancer and Therapeutics) consortiums. The partnerships will collectively receive nearly €12 million in ...

Agendia Announces Colorectal Cancer Research Collaboration with MD Anderson Cancer Center and Netherlands Cancer Institute

14-Jun-2011 - Agendia announced that it has entered into a research collaboration with The University of Texas MD Anderson Cancer Center and the Netherlands Cancer Institute (NKI) with the aim of improving diagnosis and treatment options of colorectal cancer patients. The work is based on an approach toward ...

Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists

11-Feb-2010 - Agendia announced that it has received the Clinical Laboratory Permit from the New York State Department of Health. The New York State permit allows the company to receive commercial samples of MammaPrint, its FDA-cleared breast cancer recurrence test. With this latest permit, Agendia has now ...

Agendia's MammaPrint shows significant agreement with other multi-gene breast cancer prognosis tests

22-Aug-2006 - In a publication in the New England Journal of Medicine, Agendia's MammaPrint® 70 gene breast cancer prognosis test and three other multi gene tests are shown to be superior over conventional assessment of risk of future metastatic disease. This reinforces the reliability of multi-gene tests for ...